Literature DB >> 26569152

Anxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS.

Sarah A Morrow1, Heather Rosehart1, Koula Pantazopoulos1.   

Abstract

Cognitive impairment, anxiety, and depressive symptoms are common in multiple sclerosis (MS) and are known to interact in non-MS populations. This retrospective chart review examined this relationship in a relapsing-remitting MS population. A significant difference on measures of processing speed/working memory and visual-spatial memory was found in MS patients with anxiety compared with nonanxious MS patients, while a significant difference was found on measures of processing speed, visual-spatial memory and executive function in MS patients with depressive symptoms compared with those without. Further research is needed to determine the causal relationship between anxiety and depressive symptoms and cognitive impairment.

Entities:  

Mesh:

Year:  2015        PMID: 26569152     DOI: 10.1176/appi.neuropsych.15070167

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  15 in total

Review 1.  Psychiatric disorders in multiple sclerosis.

Authors:  Maddalena Sparaco; Luigi Lavorgna; Simona Bonavita
Journal:  J Neurol       Date:  2019-06-13       Impact factor: 4.849

Review 2.  Comorbidity in multiple sclerosis: implications for patient care.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2017-03-17       Impact factor: 42.937

3.  The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a.

Authors:  Hanne van Ballegooijen; Karin van der Hiele; Christian Enzinger; Gert de Voer; Leo H Visser
Journal:  eNeurologicalSci       Date:  2022-06-14

4.  Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patients.

Authors:  Seyed-Parsa Hojjat; Charles Grady Cantrell; Timothy J Carroll; Rita Vitorino; Anthony Feinstein; Lying Zhang; Sean P Symons; Sarah A Morrow; Liesly Lee; Paul O'Connor; Richard I Aviv
Journal:  Mult Scler       Date:  2016-02-04       Impact factor: 6.312

5.  Relationship Between Anxiety and Cognition in Multiple Sclerosis: Implications for Treatment.

Authors:  Nicholas A Vissicchio; Caroline Altaras; Amanda Parker; Shonna Schneider; Jeffrey G Portnoy; Roseanne Archetti; Marnina Stimmel; Frederick W Foley
Journal:  Int J MS Care       Date:  2019 Jul-Aug

6.  Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.

Authors:  Giulia DiGiuseppe; Mervin Blair; Sarah A Morrow
Journal:  Int J MS Care       Date:  2018 Jul-Aug

7.  Cognitive status in patients with multiple sclerosis in Lanzarote.

Authors:  María Yaiza Pérez-Martín; Pablo Eguia-Del Río; Montserrat González-Platas; Alejandro Jiménez-Sosa
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-30       Impact factor: 2.570

8.  Multiple sclerosis in First Nations Canadians: A pilot comparison study.

Authors:  Ruth Ann Marrie; Nicholas Hall; A Dessa Sadovnick
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-08-29

9.  Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.

Authors:  Ruth Ann Marrie; Ronak Patel; Charles N Bernstein; James M Bolton; Lesley A Graff; James J Marriott; Carol A Hitchon; Chase R Figley; Jennifer Kornelsen; John D Fisk
Journal:  Mult Scler       Date:  2020-09-25       Impact factor: 6.312

Review 10.  Recommendations for cognitive screening and management in multiple sclerosis care.

Authors:  Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.